Procter & Gamble replaces CEO Moeller with COO and long-time executive Jejurikar

Procter & Gamble replaces CEO Moeller with COO and long-time executive Jejurikar


Jon R. Moeller

Source: Procter & Gamble

Procter & Gamble CEO Jon Moeller is stepping away from the top job after four years in the role, and the consumer goods giant said he would be succeeded by Chief Operating Officer Shailesh Jejurikar.

Moeller will become executive chairman and “provide advice and counsel to the CEO on company matters,” P&G said in a statement on Monday, a day before it was scheduled to report its quarterly results.

The company did not disclose the reason for the change in leadership in its statement, but P&G chief communications officer Damon Jones told Reuters Moeller’s departure was part of a planned and orderly transition made by the board. There were no health concerns leading to Moeller’s departure, he said.

The Cincinnati, Ohio-based company has a history of relatively short CEO terms, dating back to the mid-1990s.

Moeller’s predecessor David Taylor was CEO for six years, two of which were during the COVID pandemic when consumer goods companies faced product shortages and supply chain snags. Taylor then served as executive chairman of the board.

Under Moeller, the company navigated a post-pandemic sales boom, as well as rising expenses and sticky inflation. P&G shares gained roughly 13% during his four-year tenure, in line with the S&P 500 index.

The company, which makes Pampers diapers and Head & Shoulders shampoo, in April warned of higher product prices due to an increase in input costs from the trade war at a time of weakening consumer spending. Its stock is down about 6% so far this year.

In June, the company said it would cut 7,000 jobs over the next two years and exit some product categories and brands in certain markets, including some potential divestitures, as part of a broader two-year restructuring plan.

“It might not mean much to the outlook since they’re promoting from within,” said Brian Jacobsen, chief economist at Annex Wealth Management, which holds P&G shares. “This could be more like the passing of the baton in a long race rather than shaking things up.”

Jejurikar’s appointment, effective January 1, 2026, keeps up with P&G’s preference for naming internal candidates for the top job. Moeller had also risen through the ranks before becoming the COO and then CEO of the company.

The board has nominated Jejurikar as a director at the annual shareholder meeting in October 2025.

Jejurikar has held roles across multiple P&G businesses, including Health & Beauty Care and P&G Professional. Prior to his current role, he was the head of P&G’s Fabric & Home Care, which includes brands such as Tide, Ariel and Downy.



Source

PayPal beats on earnings, raises full-year outlook as Venmo growth accelerates
World

PayPal beats on earnings, raises full-year outlook as Venmo growth accelerates

PayPal reported better-than-expected results for the second quarter and raised its full-year guidance for transaction margin dollars and earnings per share. The stock slipped more than 4% following the report. Here’s how the company did compared with Wall Street estimates, based on a survey of analysts by LSEG: Earnings per share: $1.40 adjusted vs. $1.30 expected […]

Read More
Novo Nordisk shares plunge 17% after Wegovy-maker cuts full-year guidance
World

Novo Nordisk shares plunge 17% after Wegovy-maker cuts full-year guidance

Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background. Nurphoto | Nurphoto | Getty Images Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth expectations for its Wegovy obesity drug in the key U.S. market. Shares were […]

Read More
Pharma giants push for tariff clarity as ambiguity threatens EU-U.S. deal
World

Pharma giants push for tariff clarity as ambiguity threatens EU-U.S. deal

Shelf of pharmaceutical products. D3sign | Moment | Getty Images Pharma firms are calling for clarity on tariffs imposed under the new U.S.-EU trade agreement, as analysts warn that punitive sector-specific levies could risk blowing up the entire deal. Ambiguity abounds around the terms for pharmaceutical goods under the trade truce agreed Sunday, which imposes […]

Read More